Search Results - "Sibaud, V"

Anticancer treatments and photosensitivity by Sibaud, V.

“…Drug‐induced photosensitivity is associated with a wide range of anticancer treatments, including conventional chemotherapeutic agents, targeted anticancer…”
Get full text

Supportive oncodermatology is the key by Parriel, E, Sibaud, V

Get full text

Oral mucosal toxicities induced by immune checkpoint inhibitors: Clinical features and algorithm management by Vigarios, E., Sibaud, V.

“…Immune checkpoint inhibitors (ICIs) have emerged as standard therapies for an increasing number of advanced cancers. Nonspecific immune activation may lead to…”
Get full text

Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice by Sibaud, V., Sollena, P.

“…Cyclin-dependent kinase (CDK) 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) have revolutionized the treatment of metastatic breast carcinoma. They…”
Get full text

IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy by Gutzmer, R., Sibaud, V., Hassel, J.C.

Get full text

Immune‐related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors by Zarbo, A., Belum, V.R., Sibaud, V., Oudard, S., Postow, M.A., Hsieh, J.J., Motzer, R.J., Busam, K.J., Lacouture, M.E.

“…Summary Cytotoxic T‐lymphocyte‐associated protein‐4, programmed cell death protein and programmed cell death protein ligand 1 monoclonal antibodies (immune…”
Get full text

Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines by Lacouture, M.E., Sibaud, V., Gerber, P.A., van den Hurk, C., Fernández-Peñas, P., Santini, D., Jahn, F., Jordan, K.

“…•This ESMO Clinical Practice Guideline provides recommendations on the prevention/management of dermatological toxicities.•Authorship includes a…”
Get full text

Corrigendum to ‘IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy’: Annals of Oncology 2021; volume 32: 696-697 by Gutzmer, R., Sibaud, V., Hassel, J.C.

Get full text

PATEO syndrome by Lacroix, N., Anghel, D., Sibaud, V.

Get full text

Nivolumab-induced poliosis restricted to a tattoo: A coincidental association? by Kluger, N., Marcaillou, M., Sibaud, V.

Get full text

Autoimmune bullous diseases induced by cyclin-dependent kinase 4/6 inhibitors-first cohort from the EADV Task Force 'Dermatology for Cancer Patients' by Ortiz-Brugués, A, Starace, M, Bardazzi, F, Koumaki, D, Apalla, Z, Iorizzo, M, Bost, C, Tournier, E, Milesi, S, Lacaze, J L, Peris, K, Sollena, P, Sibaud, V

Get more information

Efficacy of dupilumab in eosinophilic dermatosis of haematologic malignancy (EDHM) needs to be confirmed by Sibaud, V., Brun, A., Meyer, N., Oberic, L., Lamant, L., Ysebaert, L.

Get full text

European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement by Apalla, Z., Nikolaou, V., Fattore, D., Fabbrocini, G., Freites‐Martinez, A., Sollena, P., Lacouture, M., Kraehenbuehl, L., Stratigos, A., Peris, K., Lazaridou, E., Richert, B., Vigarios, E., Riganti, J., Baroudjian, B., Filoni, A., Dodiuk‐Gad, R., Lebbé, C., Sibaud, V.

“…The introduction of immune checkpoint inhibitors (ICIs) opened a new era in oncologic therapy. The favourable profile of ICIs in terms of efficacy and safety…”
Get full text

Morphea‐like changes in the setting of cancer immunotherapy by De Simone, C., Mannino, M., Sollena, P., Deilhes, F., Sibaud, V., Peris, K.

“…Immune checkpoint inhibitors (ICI) are monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1…”
Get full text

Clinical, biological and histological characteristics of bullous pemphigoid associated with anti‐PD‐1/PD‐L1 therapy: A national retrospective study by Juzot, C., Sibaud, V., Amatore, F., Mansard, S., Seta, V., Jeudy, G., Pham‐Ledard, A., Benzaquen, M., Peuvrel, L., Le Corre, Y., Lesage, C., Viguier, M., Baroudjian, B., Dréno, B., Quéreux, G.

Get full text

Complete response of a metastatic porocarcinoma treated with paclitaxel, cetuximab and radiotherapy by Godillot, C., Boulinguez, S., Riffaud, L., Sibaud, V., Chira, C., Tournier, E., Paul, C., Meyer, N.

“…A case of a patient with metastatic eccrine porocarcinoma (EP) who initially displayed an almost complete response after treatment with paclitaxel, cetuximab…”
Get full text

Oral lichenoid reactions associated with anti‐PD‐1/PD‐L1 therapies: clinicopathological findings by Sibaud, V., Eid, C., Belum, V.R., Combemale, P., Barres, B., Lamant, L., Mourey, L., Gomez‐Roca, C., Estilo, C.L., Motzer, R., Vigarios, E., Lacouture, M.E.

Get full text

Oral mucosal pigmentation induced by vandetanib therapy: First clinicopathological characterization by Vigarios, E., Maret, D., Herbaut-Barres, B., Zerdoud, S., Sibaud, V.

Get full text

Spider‐like injection site reaction after subcutaneous administration of haematological treatments by Plume, M‐A., Sibaud, V., Bobin, A., Hainaut, E., Frouin, E., Masson Regnault, M.

Get full text

Management of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paper based on the first Europe/USA Delphi consensus process by Apalla, Z, Freites-Martinez, A, Grafanaki, K, Ortiz-Brugues, A, Nikolaou, V, Fattore, D, Sollena, P, Deverapalli, S, Babakoohi, S, Galimont, A, Kluger, N, Beylot-Barry, M, Larocca, C, Iriarte, C, Smith, J, Tattersall, I, Dodiuk-Gad, R, Sauder, M, Carrera, C, Kwong, B, Whitley, M, Leboeuf, N, Romano, P, Starace, M, Mateeva, V, Riganti, J, Hirner, J, Patel, A B, Reyes-Habito, C M, Kraehenbuehl, L, Kheterpal, M, Fida, M, Hassel, J, Lacouture, M, Sibaud, V

“…There is a need for unified guidance in the management of acneiform rash induced by epidermal growth factor receptor inhibitors (EGFRi) among dermatologists…”
Get full text